BACKGROUND: Atherosclerosis is a complex vascular inflammatory disease. Low-dose aspirin is a mainstay in the prevention of vascular complications of atherosclerosis. We wished to determine the effect of low-dose aspirin on vascular inflammation, plaque composition, and atherogenesis in LDL receptor-deficient mice fed a high fat diet. METHODS AND RESULTS: In LDL receptor-deficient mice fed a high fat diet compared with control mice, low-dose aspirin induced a significant decrease in circulating levels and vascular formation of soluble intercellular molecule-1, monocyte chemoattractant protein-1, tumor necrosis factor-alpha, interleukin-12p 40, without affecting lipid levels. This was associated with significant reduction of the nuclear factor kappaB activity in the aorta. Low-dose aspirin also significantly reduced the extent of atherosclerosis. Finally, aortic vascular lesions of the aspirin-treated animals showed 57% reduction (P<0.05) in the amount of macrophage cells, 77% increase in smooth muscle cells (P<0.05), and 23% increase in collagen (P<0.05). CONCLUSIONS: Our results suggest that in murine atherosclerosis, low-dose aspirin suppresses vascular inflammation and increases the stability of atherosclerotic plaques, both of which, together with its antiplatelet activity, contribute to its antiatherogenic effect. We conclude that low-dose aspirin might be rationally evaluated in the progression and evolution of human atherosclerotic plaque.
BACKGROUND:Atherosclerosis is a complex vascular inflammatory disease. Low-dose aspirin is a mainstay in the prevention of vascular complications of atherosclerosis. We wished to determine the effect of low-dose aspirin on vascular inflammation, plaque composition, and atherogenesis in LDL receptor-deficient mice fed a high fat diet. METHODS AND RESULTS: In LDL receptor-deficient mice fed a high fat diet compared with control mice, low-dose aspirin induced a significant decrease in circulating levels and vascular formation of soluble intercellular molecule-1, monocyte chemoattractant protein-1, tumor necrosis factor-alpha, interleukin-12p 40, without affecting lipid levels. This was associated with significant reduction of the nuclear factor kappaB activity in the aorta. Low-dose aspirin also significantly reduced the extent of atherosclerosis. Finally, aortic vascular lesions of the aspirin-treated animals showed 57% reduction (P<0.05) in the amount of macrophage cells, 77% increase in smooth muscle cells (P<0.05), and 23% increase in collagen (P<0.05). CONCLUSIONS: Our results suggest that in murineatherosclerosis, low-dose aspirin suppresses vascular inflammation and increases the stability of atherosclerotic plaques, both of which, together with its antiplatelet activity, contribute to its antiatherogenic effect. We conclude that low-dose aspirin might be rationally evaluated in the progression and evolution of humanatherosclerotic plaque.
Authors: Morgan B Elliott; Brian Ginn; Takuma Fukunishi; Djahida Bedja; Abhilash Suresh; Theresa Chen; Takahiro Inoue; Harry C Dietz; Lakshmi Santhanam; Hai-Quan Mao; Narutoshi Hibino; Sharon Gerecht Journal: Proc Natl Acad Sci U S A Date: 2019-06-10 Impact factor: 11.205
Authors: Saske Hoving; Sylvia Heeneman; Marion J J Gijbels; Johannes A M te Poele; Manlio Bolla; Jeffrey F C Pol; Michelle Y Simons; Nicola S Russell; Mat J Daemen; Fiona A Stewart Journal: PLoS One Date: 2010-09-21 Impact factor: 3.240
Authors: Jung Ok Ban; Ju Hoon Oh; Tae Myoung Kim; Dae Joong Kim; Heon-Sang Jeong; Sang Bae Han; Jin Tae Hong Journal: Arthritis Res Ther Date: 2009-09-30 Impact factor: 5.156